A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
Latest Information Update: 10 Jun 2024
At a glance
- Drugs JNJ 73763989 (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
- 20 Jul 2022 Results (n=84) assessing afety and efficacy of the small interfering RNA JNJ-73763989 (JNJ-3989) plus a nucleos(t)ide analogue (NA), with/without the capsid assembly modulator JNJ-56136379 in patients with chronic hepatitis B, published in the Journal of Hepatology.
- 26 Jun 2021 Results assessing baseline factors associated with HBsAg reduction and compared the effect of JNJ-3989 against the viral markers HBsAg, HBeAg, HBcrAg and HBV RNA presented at The International Liver Congress 2021
- 29 Aug 2020 Results presented at The International Liver Congress 2020